Veser Charlotte, Carlier Aurélie, Dubois Vanessa, Mihăilă Silvia M, Swapnasrita Sangita
Utrecht Institute for Pharmaceutical Sciences, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands.
MERLN Institute for Technology-Inspired Regenerative Medicine, Universiteitssingel 40, 6229 ER, Maastricht, The Netherlands.
Biol Sex Differ. 2024 Dec 2;15(1):99. doi: 10.1186/s13293-024-00662-8.
In vitro models serve as indispensable tools for advancing our understanding of biological processes, elucidating disease mechanisms, and establishing screening platforms for drug discovery. Kidneys play an instrumental role in the transport and elimination of drugs and toxins. Nevertheless, despite the well-documented inter-individual variability in kidney function and the multifaceted nature of renal diseases-spanning from their origin, trigger and which segment of the kidney is affected-to presentation, progression and prognosis, few studies take into consideration the variable of sex. Notably, the inherent disparities between female and male biology warrants a more comprehensive representation within in vitro models of the kidney. The omission of sex as a fundamental biological variable carries the substantial risk of overlooking sex-specific mechanisms implicated in health and disease, along with potential differences in drug responsiveness and toxicity profiles between sexes. This review emphasizes the importance of incorporating cellular, biological and functional sex-specific features of renal activity in health and disease in in vitro models. For that, we thoroughly document renal sex-specific features and propose a strategic experimental framework to integrate sex-based differences into human kidney in vitro models by outlining critical design criteria to elucidate sex-based features at cellular and tissue levels. The goal is to enhance the accuracy of models to unravel renal mechanisms, and improve our understanding of their impact on drug efficacy and safety profiles, paving the way for a more comprehensive understanding of patient-specific treatment modalities.
体外模型是增进我们对生物过程的理解、阐明疾病机制以及建立药物发现筛选平台不可或缺的工具。肾脏在药物和毒素的转运与清除中发挥着重要作用。然而,尽管肾功存在个体间差异且肾脏疾病具有多方面特性(从起源、触发因素以及受影响的肾脏节段到临床表现、进展和预后)已被充分记录,但很少有研究考虑性别变量。值得注意的是,雌性和雄性生物学之间的固有差异使得肾脏体外模型需要更全面的呈现。将性别作为一个基本生物学变量的遗漏,极有可能忽视与健康和疾病相关的性别特异性机制,以及两性之间药物反应性和毒性特征的潜在差异。本综述强调了在体外模型中纳入健康和疾病状态下肾脏活动的细胞、生物学和功能性性别特异性特征的重要性。为此,我们详尽记录了肾脏性别特异性特征,并提出了一个战略实验框架,通过概述关键设计标准以在细胞和组织水平阐明基于性别的特征,从而将基于性别的差异整合到人类肾脏体外模型中。目标是提高模型解析肾脏机制的准确性,并增进我们对其对药物疗效和安全性特征影响的理解,为更全面地理解针对患者的治疗方式铺平道路。